Pfizer Inc Sells 594,804 Shares of Bolt Biotherapeutics, Inc. $BOLT

Pfizer Inc decreased its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 95.0% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 31,305 shares of the company’s stock after selling 594,804 shares during the period. Bolt Biotherapeutics makes up about 0.0% of Pfizer Inc’s holdings, making the stock its 18th biggest holding. Pfizer Inc’s holdings in Bolt Biotherapeutics were worth $181,000 at the end of the most recent quarter.

Wall Street Analyst Weigh In

BOLT has been the topic of a number of recent research reports. Lake Street Capital raised their price objective on Bolt Biotherapeutics to $75.00 and gave the company a “buy” rating in a research note on Friday, August 15th. Zacks Research raised Bolt Biotherapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Wednesday, October 8th. Finally, HC Wainwright set a $7.00 target price on shares of Bolt Biotherapeutics and gave the stock a “buy” rating in a research note on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $34.00.

Bolt Biotherapeutics Stock Down 1.3%

Shares of NASDAQ:BOLT opened at $4.51 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.57 and a current ratio of 3.57. Bolt Biotherapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $13.00. The firm has a market capitalization of $8.66 million, a P/E ratio of -0.20 and a beta of 0.92. The stock has a 50 day moving average price of $5.43 and a 200-day moving average price of $5.76.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($3.72) EPS for the quarter, beating the consensus estimate of ($5.07) by $1.35. The firm had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $0.82 million. As a group, equities research analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.